# BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

> **NCT00779064** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 36 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban (BAY59-7939)
- **DRUG:** Rivaroxaban (BAY59-7939)

## Key facts

- **NCT ID:** NCT00779064
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-12-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00779064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00779064, "BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00779064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*